HUTCHMED (China) Limited ADR (HCM)
HUTCHMED (China) Limited (HCM) Q2 2024 Earnings Call Transcript
HUTCHMED (China) Limited (NASDAQ:HCM ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants David Ng - Head:Investor Relations Wei-Guo Su - Chief Executive Officer & Chief Scientific Officer Johnny Cheng - Chief Financial Officer George Yuan - Head of Commercial Michael Shi - Executive Vice President, Head of R&D & Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Chen Chen - UBS Clara Dong - Jefferies Adam McCarter - Cavendish Paul Choi - Goldman Sachs Julie Simmonds - Panmure Liberum David Ng Hello, everyone. Welcome to HUTCHMED 2014 Interim Results Presentation.
Paycom: Initiating Buy On Strong Growth Tailwind And BETI Pricing Power
Paycom is recommended as a buy due to its long-term growth potential and strong value proposition with its BETI product. The global HCM software industry is expected to grow, providing opportunities for cloud-based HCM solutions like PAYC. The revised sales strategy and international expansion are expected to drive customer satisfaction and future growth for PAYC.
